Roctavian (valoctocogene roxaparvovec-rvox) FDA approval

FDA-approved use

the treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity <1 IU/dL) without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test.Production InformationPackage Insert - ROCTAVIANDemographic Subgroup Information – valoctocogene roxaparvovec-rvox (ROCTAVIAN)Refer to Section 1.1 of the Clinical Review Memo for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Roctavian:

"What was the basis for Roctavian's approval — what trials, what endpoints?"

"What adverse events did the FDA flag in the Roctavian medical review?"

"What regulatory pathway did Roctavian use — priority review, breakthrough, accelerated approval?"

Roctavian

Approval

FDA-approved use

Approval package

Query with Claude